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esses: nurtenaksoy@yahSummary Background: Reactive nitrogen, oxygen species and oxidative stress are
related to many pulmonary diseases. Nitric oxide (NO) may be involved in either the
protection against or the induction of oxidative stress within various tissues. It is
derived from the amino acid L-arginine by the action of NO synthase (NOS). L-arginine
can also be metabolized by arginase with the production of ornithine and urea.
Because of the competition between NOS and arginase for the same substrate, their
activities are regulated reciprocally. Therefore, the rate of NO generation associated
with oxidative stress is dependent on the relative activities of both NOS and
arginase. The objective of this study is to investigate the L-arginine–NO pathway,
evaluate oxidative–antioxidative status in the patients with asthma and demonstrate
their reciprocal regulation.
Methods: 30 voluntary asthmatic patients and 30 healthy control subjects with
similar age range and sex were included in the study. A total of 10ml venous blood
was drawn, plasma and packed erythrocytes were prepared for the biochemical
analyses. Plasma arginase activities and NO levels, and erythrocyte malondialdehyde
and reduced glutathione levels were detected.
Results: Plasma malondialdehyde levels were significantly higher and glutathione
levels were lower in patients with asthma than those of the control subjects
(Po0:001 and Po0:01; respectively). Arginase activities were significantly lower and
NO levels were higher in the patients than those of the controls (Po0:001 for both).
The negative correlation between arginase and NO levels in the patients was
significant (r ¼ 0:47; Po0:01). There was also a positive correlation between
malondialdehyde and NO levels in the patients (r ¼ 0:51; Po0:01).Elsevier Ltd. All rights reserved.
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pathophysiology of asthma; the arginase activities decrease which causes an
increase in the L-arginine levels thereby up-regulation of NO production may
contribute to the increase of oxidative stress in asthma.
& 2004 Elsevier Ltd. All rights reserved.Introduction
It has been proposed that reactive oxygen and
nitrogen species, both formed in infected and
inflamed tissues, play roles in oxidative stress
which cause damage on biomolecules such as lipids,
proteins and nucleic acids, each by a different
mechanism. Nitric oxide (NO), a potentially toxic
gas with free radical properties, is generated from
L-arginine by constitutive or inducible NO synthase
(NOS). It is important to note that NO is a
modulator of cellular function and can act either
as a cellular messenger or, when produced in excess
quantities, as pro-oxidant, inducing oxidative
stress.1–3 Under normal conditions, NO interacts
with superoxide anion to protect lungs against
superoxide, but when NO and superoxide are both
produced in very high quantities they react rapidly
to form the very powerful oxidant peroxynitrite,
which may contribute to lung injury.2–5
The relation between exhaled NO and asthma
status was recently defined in several studies of
asthma.1–8 The NO was found to be elevated in
asthmatic patients with evidence of atopy, whereas
non-atopic asthmatic patients, atopic non-asth-
matic patients, and non-atopic non-asthmatic
patients did not have raised levels of exhaled NO.
These data imply a relation between asthma
severity, NO production, and oxidative stress.7
However, as cited by Baraldi and Zanconato,
patients with asthma are clinically diverse, have
variable levels of exhaled NO, and it is difficult to
distinguish asthmatic patients using exhaled NO
levels.8 Moreover, the source of NO in airways is not
only endogenous but also exogenous as a conse-
quence of air pollution and smoking.6,9 Therefore,
a further step is required to evaluate NO as an
indicator for the disease.
Since NO is synthesized from L-arginine by NOS
which competes with arginase for the same
substrate, we should theoretically expect a reci-
procal relation between them. Changes in L-
arginine metabolism during inflammation are not
limited to effects of NOS but can also involve
arginases whose two types are well known; arginase
I is termed as liver-type arginase and located in the
cytosol, and arginase II is termed as non-hepatic
type and located in the mitochondrial matrix,
which can modulate NO synthesis and produceornithine for the generation of polyamines and
proline. The latter are important molecules in-
volved in tissue damage and repair during inflam-
mation. The links with the L-arginine–NO pathway
and collagen generation make L-arginine metabo-
lism a rising star in the asthmatic process. Arginase
I and II were recently shown to contribute to the
development of mouse lung fibrosis as cited by
Vercelli.10 Thus, the L-arginine–NO pathway should
be elaborated to better understanding the correla-
tion of NO, asthma and oxidative stress, which is
still unresolved, and we will try to put a light on it
in this work.Material and methods
The study was conducted on 30 patients with
asthma who applied to the outpatients department
of the Chest Diseases Clinic, Harran University-
Research Hospital and evaluated according to the
International GINA Asthma Consensus Guidelines.11
and on 30 healthy volunteers. The ages and sexes
and the rate of smoking of the patients and controls
were similar. None of them had allergic rhinitis,
eczema or hay fever. All the patients had mild
asthma without having an acute exacerbation
during the last 3 months. They had no other
infectious condition and/or diagnosed disease. All
patients were regularly taking inhaled corticoster-
oids at low doses and short-acting b2 agonist when
they needed. None of them used teophylline,
antihistaminik, oral corticosteroid and leukotriene
receptor antagonist. All of the patients and
controls were put on a standard diet and given up
the treatment for 3 days before laboratory ana-
lyses. After 3 days with a standard diet, all subjects
were taken to a fasting duration between
16.00 p.m. and 08.00 a.m. for about 16 h. All
patients and control were examined physically
and analysed for forced vital capacity (FVC), forced
expiratory volume in 1 s (FEVı), FEV1/FVC, peak
expiratory flow (PEF), early reversibility test, skin
prick test and biochemical analyses. None of the
patients had allergy profile. After their physical and
laboratory examination, all patients were taken to
the treatment according to the Asthma Consensus
guidelines.11
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containing tubes and centrifuged at 1500g for
10min, to separate the plasma. Packed erythro-
cytes were washed with normal saline three times.
Preparation of washed erythrocyte and biochemical
analyses were performed immediately after blood
collection.
NO reacts with molecular oxygen and accumu-
lates in the plasma as nitrite (NO2
) and nitrate
(NO3
) ions. Thus, the stable oxidation end products
of NO, NO2
 and NO3
 can be readily measured in
biological fluids and used in vitro and in vivo as
indicators of NO production. Plasma nitrite levels
were measured with Griess reaction.12 Briefly,
samples were initially deproteinized with Somogyi
reagent.13 Total nitrite (nitrite+nitrate) was mea-
sured after the conversion of nitrate to nitrite by
copporized cadmium granules by a spectrophot-
ometer at 545 nm (Ultraspect Plus, Pharmacia LKB
Biochrom Ltd, UK). Results were expressed as
micromoles per litre plasma.
Plasma arginase activity was measured according
to the method of Geyer and Dabich14 with some
modification for plasma. Briefly, plasma was diluted
10 times with a solution of 5mmol/l Mn2+ and
incubated for 8min at 55 1C (preincubation). Then
0.2ml preincubated plasma, 0.4ml 25mmol/l L-
arginine, and 0.4ml 40mmol/l carbonate buffer
(pH: 9.7) were incubated for 60min at 37 1C. After
incubation, the reaction was stopped and the
sample was deproteinized by adding 0.5ml of 1 N
HClO4. Urea level was measured spectrophotome-
trically through the method of thiosemikarbazid-
diasetilmonoksim-urea in the supernatants. The
specific enzyme activity was expressed as U/g
protein.
The erythrocyte MDA was estimated by the
method of Jain et al.15 based on thiobarbituric
acid (TBA) reactivity. MDA reacts with TBA to form
a coloured complex that has a maximum absor-Table 1 Characteristics of the patients with asthma and
Parameters Asthmatic pa
Sex, M/F 13/17
Smokers, yes/no 0/30
Age (years) 35.8711.72
FEV1 (%) 73.8576.89
FVC (%) 79.44718.4
FEV1/FVC 59.22716.4
PEF (l/s) 56.70717.7
Short-acting beta-2 agonists use 0/30
Inhaled corticosteroids use 30/30
The values represent the mean7SD.bance at 532 nm. The MDA concentration in
erythrocytes was expressed as U/g Hb.
The erythrocyte reduced glutathione (GSH) con-
tent was determined by the method of Beutler
et al.16 Virtually all of the non-protein sulphydryl
groups of red blood cells are in the form of GSH.
5,50-Dithiobis(2-nitrobenzoic acid) is a disulphide
chromogen that is readily reduced by sulphydryl
compounds to an intensely yellow compound. The
absorbance of the reduced chromogen is measured
at 412 nm and is directly proportional to the GSH
concentration.
Data were analysed using SPSSs 10.0 for Win-
dows program. Parametric statistical methods were
used to analyse the data. The student’s t-tests
were used for pair-wise comparisons. Bivariate
comparisons were done using Pearson’s rank corre-
lation coefficients (r) and values were corrected for
ties. Two-tailed significance values were used. A P
value of 0.05 or less was considered to be
significant.Results
The social and demographic data (age, sex, etc.) of
the patients and their controls showed homogene-
ity, and there were no significant differences
between the groups (P40:05). The patients de-
monstrated 79.44718.43 FVC and 73.8576.89
FEV1. The general characteristics of the patients
and controls are shown in Table 1.
The erythrocyte MDA concentrations were in-
creased in asthmatic patients compared with the
controls (Po0:001). GSH levels were decreased in
erythrocytes of the asthmatic patients compared
with the controls (Po0:01).
Plasma arginase activities of patients with
asthma were significantly lower (Po0:001) whereasthe healthy controls.
tients (n ¼ 30) Healthy controls (n ¼ 30)
12/18
0/30
34.979.79
106.1719.26
3 101.5712.12
1 106.878.46
2 85715.78
0/30
0/30
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Table 2 Plasma arginase activities, nitric oxide levels and erythrocyte MDA and GSH levels of the asthmatic
patients and the healthy controls.
Parameters Control groups (n ¼ 30) Asthma (n ¼ 30) P* value
Arginase (U/g protein) 10.1275.4 2.7573.2 o0.001
Total nitrite (mmol/L) 12.4572.0 16.4672.1 o0.001
MDA (nmol/g Hb) 1.3670.33 1.8070.37 o0.001
GSH (mmol/g Hb) 20.6574.86 15.9276.63 o0.01
The values represent mean7SD.
*Significance was defined as Po0:05:
Table 3 Correlation of arginase–NO and MDA–NO
in patients with asthma.
Parameters r P* value
Arginase–NO 0.47 o0.01
MDA–NO 0.51 o0.01
*Significance was defined as Po0:05:
E. Ceylan et al.874plasma total nitrite, a product of L-arginine–NO
pathway, levels were significantly higher (Po0:001)
than those of controls. The results were summar-
ized in Table 2. A significant negative correlation
(r ¼ 0:47; Po0:01) was detected between plasma
arginase activities and plasma NO levels indicating
their reciprocal regulation in the L-arginine–NO
pathway and positive correlation (r ¼ 0:51;
Po0:01) was detected between plasma MDA and
NO levels (Table 3).Discussion
It is well known that many cell types utilize L-
arginine to generate NO, which plays important
roles in many diverse processes including vasodila-
tation, bronchodilatation, immune responses, neu-
rotransmission, and adhesion of platelets and
leukocytes.17,18 The discovery of the novel L-
arginine-dependent NO pathway has stimulated
renewed interest in the biochemistry and physiol-
ogy of L-arginine metabolism in which NOS, whose
product NO, and arginase, whose products urea and
ornithine, compete for the same subtract. Due to
the relationship between NO and L-arginine meta-
bolism, NO level alone would not be an indicator
for the disorders. In particular, changes in the
activities of arginase, which is thought to be a
marker for asthma,10 and the products of NO
namely NO2
 and NO3
 might play major roles in
determining metabolic fates of the L-arginine–NOpathway in health and diseases, and the current
study was designed with the aim to investigate the
possible changes of this pathway in asthma.
Asthma is a consequence of an underlying chronic
inflammatory disorder of the airways involving
many cells, in particular mast cells, eosinophils,
neutrophils, and T lymphocytes, and the airway
epithelium, with the participation of a number of
mediators.4–7 The mediators released from acti-
vated mast cells and eosinophils such as ROS
generate oxidative stress, known as oxidants, that
contributes to tissue injury and asthma symptoma-
tology. Other airway oxidants in asthma include NO,
a free radical released by activated leukocytes and
the airway epithelium as a consequence of chronic
inflammation, peroxynitrite and hypochlorous
acid.2,3,8,9 Important exogenous oxidants include
nitrogen dioxide and ozone as a consequence of air
pollution. Cigarette smoke is a particularly rich
source of NO and nitrogen dioxide.6,8 Gutierrez et
al.6 reported that when cultured pulmonary epithe-
lial cells and lung tissue in vivo are subjected to
inflammatory mediators or acute oxidative stress,
NO can play a protective role by inhibiting O2
-
dependent toxicity. In their in vitro rodent model of
pulmonary oxidant injury, they demonstrated that
NO decreases epithelial permeability caused by
ROS and thus helps defend against tissue injury
subsequent to oxidative stress.6 In the present
study, we found that NO levels were higher in
asthmatic patients than in healthy controls. How-
ever, it is still controversial whether this increase is
beneficial or damaging.7–9,19 As a bronchodilator,
inhalation of high concentrations of NO may be
beneficial in asthmatic patients by counteracting
the bronchoconstriction produced by inflammatory
mediators such as leukotriene D4.7,8,20 On the other
hand, there are several controversies in the
literature about the damaging effects of increased
NO levels in asthma indicating that the NO may
amplify asthmatic inflammation by altering the
balance between T helper type 1 and T helper type
2 cells and increase bronchial blood flow thereby
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we detected an imbalance between oxidative and
antioxidative system by measuring LPO that was
significantly high in the asthmatic patients, and
GSH that reduces free radical and was very low in
the patients compared to the controls. We found a
significant positive correlation between plasma
MDA and NO levels which provided an evidence
for the contribution of NO to the increased
oxidative stress in asthma.21 The susceptibility of
the body to oxidative injury depends largely on its
ability to up-regulate protective free radical and
ROS scavenging systems such as GSH. However, in
asthma, the body cannot increase the antioxidative
capacity and/or it increases but not enough to cope
with the oxidative stress caused by asthmatic
inflammation.
Owing to the competition between arginase and
NOS, it is supposed that these two enzymes of the L-
arginine–NO pathway may control each other’s
levels.18,22 Therefore, we thought that the high
NO levels in this work may result from a decrease in
the arginase activity because of their reciprocal
regulation in the pathway, and we measured
plasma arginase activities of the asthmatic patients
and controls. We found low arginase activity in our
study that supports this relationship between
arginase activity and NO levels. The possible
regulation of NO production by arginase in various
tissues is of great interest. Several diseases
associated with the impaired production or over-
production of NO, are also shown to be related to
alterations of the L-arginine metabolism.22–25 In the
light of these findings, it would be useful clinically
to prevent the overproduction of NO and hence
oxidative stress by using NOS inhibitors and/or
depressing L-arginine recycling or providing forced
induction of arginase if the L-arginine–NO pathway
is involved in the pathogenesis of disease whereby
NO levels increased and the activities of arginase
decreased.26,27
As conclusion, it is possible to underline that the
increased NO levels and decreased arginase activ-
ities indicate the involvement of the L-arginine–NO
pathway in asthma. Overproduction of NO contri-
butes to oxidative stress present in asthma that
causes worse progression of the disease giving
oxidative damage. These data may provide a new
approach to the treatment of the disease, because
the metabolic enzymes of the L-arginine–NO path-
way appear to be pertinent therapeutic targets to
control NO production in various diseases asso-
ciated with disordered NO production like asthma.
It may also be useful to add some antioxidants to
the treatment such as antioxidant vitamins like
vitamins A, C, and E.References
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